Drug intelligence / Profile preview

SYALBONE

Development stage: Unknown
Lead developer: RiverPharma
Modality: Small Molecules
Administration: Oral

Overview

SYALBONE is an oral nutraceutical supplement developed by RiverPharma, specifically formulated to support bone health and mineralization. It features a combination of high molecular weight hyaluronic acid, Vitamin K2 (menaquinone-7), Vitamin D3 (cholecalciferol), and Calcium. The product utilizes RiverPharma's specialized hyaluronic acid technology to support the bone matrix, while the vitamins and minerals work synergistically to enhance calcium absorption and ensure its proper incorporation into bone tissue, thereby assisting in the maintenance of normal bone density and the prevention of bone-related conditions like osteoporosis.

Brand names: SYALBONE

Targets

VDR (Vitamin D receptor)GGCX (Vitamin K-dependent gamma-glutamyl carboxylase)

Beyond the preview

Go deeper on SYALBONE.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SYALBONE.

Explore the full profile